EP1581043A2 - Methods for selection for efficient animal growth - Google Patents
Methods for selection for efficient animal growthInfo
- Publication number
- EP1581043A2 EP1581043A2 EP03737208A EP03737208A EP1581043A2 EP 1581043 A2 EP1581043 A2 EP 1581043A2 EP 03737208 A EP03737208 A EP 03737208A EP 03737208 A EP03737208 A EP 03737208A EP 1581043 A2 EP1581043 A2 EP 1581043A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- animals
- animal
- antigen
- selecting
- robustness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
Definitions
- the present invention relates generally to animal breeding methods. More specifically, the invention relates to methods for selecting for robustness among two or more animals based upon the quantity of immune cell subtypes and frequency of proliferative responses of lymphocytes in the animals.
- Animals have a complex array of molecular and cellular defenses, collectively referred to as the immune system, that recognize and attack potentially harmful foreign or endogenous but abnormal cells (respectively represented by, e.g., pathogens such as bacteria or viruses, and cancerous or pathogen-infected cells) , but that do not attack but rather tolerate endogenous normal cells.
- the immune system When stimulated by foreign or abnormal biomolecules, the immune system undergoes a series of activities designed to neutralize and destroy the pathogens, or cancerous or pathogen-infected cells, with which the foreign or abnormal biomolecules are associated.
- These activities collectively known as an immune response, may consist of a cell-mediated immune response, a humoral (antibody-mediated) immune response, or an immune response that includes elements of cell-mediated and humoral responses .
- Humoral immune responses are mediated by antibodies, glycoproteins that bind specific foreign or abnormal biomolecules and attract other components of the immune system thereto.
- Antibodies are immunoglobulin (Ig) molecules produced by B cells, lymphocytes which originate in avian bursa or in mammalian bone marrow but migrate to and mature in other organs, particularly the spleen (Robertson, 1983).
- Cell-mediated immune responses are the result of activities of T cells, lymphocytes that undergo maturation within the thymus of an animal (Tizard, 1988) . T cell activities vary considerably among different subpopulations of T cells within an animal.
- Cytotoxic T cells recognize and destroy foreign cells (graft rejection) or endogenous but abnormal cells (e.g., cancerous cells or cells infected with intercellular parasites such as viruses and bacteria) .
- Helper T cells interact with, and produce biomolecules that influence the behavior of, both B cells and cytotoxic T cells, in order to promote and direct antibody production and cytotoxic activities, respectively (Mosier, 1967) .
- Other classes of T cells including suppressor T cells and memory T cells, also exist (Miedema and Melief, 1983; Tizard, supra, pp. 225-8). Classes of T cells are to some extent distinguished on the basis that different T cells display different CD antigens on their surfaces.
- An antigen a molecular composition having the potential to generate an immune response, is composed of one or more molecular-sized identifying features known as epitopes.
- a polypeptide antigen which has an amino acid sequence which comprises, for example, a hundred amino acids might comprise dozens of epitopes, wherein each epitope is defined by a portion of the polypeptide comprising from about 3 to about 15 amino acids.
- T or B cell of an animal An antigen encountered by a T or B cell of an animal must be identified as either being associated with normal endogenous (i.e., self) antigens, an immune response to which would be injurious to the animal, or with foreign or abnormal (i.e., non-self) antigens, to which an immune response should be mounted.
- the process can be analogized to "friend or foe" identification in human combat. If the immune system fails to identify antigens associated with invading pathogens or tumor cells as non-self, then these "enemies" can slip through the system's defenses.
- autoimmune disease in which an animal's immune system mistakenly wages cellular and molecular "war” against another, normal part of an animal's body, is known generally as "autoimmune disease."
- autoimmune disease As part of the immune system's means of identifying antigens, individual T and B cells produce antigen receptors which are displayed on the T or B cell's surface and which bind specific antigens. Although each individual T or B cell displays identical antigen receptors, an animal's collection of different antigen receptors is quite diverse.
- T cells For T or B cells, binding of antigen to a cell's antigen receptor activates the cell, i.e., stimulates the cell to undertake activities related to generating a cell-mediated or humoral immune response.
- B cells can directly bind antigen
- T cells respond to antigen only when it is displayed on specific classes of other cells known generically as antigen- presenting cells (APCs).
- APCs e.g., macrophages and dendritic cells, present antigens derived from polypeptides via glycoproteins, known as MHC (major histocompatibility complex) proteins, which are displayed on the surface of APCs (Bevan et al . , 1994). Without MHC proteins, T cells would not be able to distinguish between foreign or endogenous antigens .
- a method for selecting for robustness among two or more animals comprising providing two or more animals of the same species; determining in each animal the quantity of CD16 antigen-expressing cells; and selecting the animal with the lowest quantity of CD16 antigen-expressing cells.
- a method for selecting for robustness among two or more animals comprising providing two or more animals of the same species; determining in each animal the quantity of CD16 and CD2 double-positive antigen-expressing cells; and selecting the animal with the lowest quantity of CD16 and CD2 double-positive antigen-expressing cells.
- a method for selecting for robustness among two or more animals comprising providing two or more animals of the same species; determining in each animal the quantity of CD8 antigen-expressing cells; and selecting the animal with the lowest quantity of CD8 antigen-expressing cells.
- a method for selecting for robustness among two or more animals comprising providing two or more animals of the same species; determining in each animal the quantity of MHC-DQ antigen-expressing cells; and selecting the animal with the highest quantity of MHC-DQ antigen-expressing cells.
- a method for selecting for robustness among two or more animals comprising providing two or more animals of the same species; determining in each animal the quantity of cells expressing an antigen that is targeted by MHC-DQ antibodies as MHC-DQB; and selecting the animal with the highest quantity of cells expressing an antigen that is targeted by MHC-DQ antibodies as MHC-DQB.
- a method for selecting for robustness among two or more animals comprising providing two or more animals of the same species; determining in each animal the quantity of cells expressing an antigen that is targeted by MHC-DQ antibodies as MHC-DQD; and selecting the animal with the highest quantity of cells expressing an antigen that is targeted by MHC-DQ antibodies as MHC-DQD.
- a method for selecting for robustness among two or more animals comprising providing two or more animals of the same species; determining in each animal the proliferation frequency of CD4 antigen-expressing cells; and selecting the animal with the lowest proliferation frequency of CD4 antigen-expressing cells.
- the species in which robustness can be selected for include, but are not limited to, Bos taurus (cow) , Sus scrofa (pig), Ovis aries (sheep), Bison bison (bison), Babalus babalus (buffalo) , Gallus do esticus (chicken) , Meleagrus gallopavo (turkey) , Anas rubripes (duck) , and Branta canadensis (goose) .
- the present invention provides methods for selecting for robustness among two or more animals. Definitions
- the terms "robust” and “robustness” are intended to refer to the general condition in an animal characterized by higher than average (1) lifetime average daily gain (ADG) , (2) hot carcass measurements, and (3) feed conversion.
- ADG lifetime average daily gain
- CD is intended to refer to cluster of differentiation. This designation is the international standard for leukocyte antigens for which monoclonal antibodies have been developed.
- the term “antibody” is intended to refer to a protein molecule synthesized by a B-cell upon exposure to antigen that is capable of combining specifically with that antigen; the term “monoclonal antibody” is intended to refer to an antibody molecule produced by a hybridoma that contains only one species of an antigen binding site capable of immunoreacting with a particular epitope of an antigen.
- a “primary” antibody is one that binds antigen directly.
- a “secondary” antibody is one that binds the primary antibody.
- the term “antigen” is intended to refer to a molecule or composition of matter which induces an immune response in an animal, and interacts specifically with antigen-recognizing components of an animal's immune system.
- mitogen is intended to refer to a compound that stimulates lymphocytes to transit through the cell cycle.
- a suitable mitogen for T-cells is Concanavalin A and phytohemagglutinin (PHA) .
- Determining Percentage of Antigen-Expressing Cells A determination of the percentage of antigen-expressing cells, including cells that express the CD16, CD2 , CD8, and MHC-DQ antigens, as well as cells expressing an antigen that is targeted by MHC-DQ antibodies as MHC-DQ bright (B) or MHC- DQ dull (D) , in an animal having such cells is preferably accomplished by isolating periperhal blood mononuclear cells (PBMCs) from the animal; incubating the PBMCs with a primary monoclonal antibody specific for the antigen of interest; labeling the PBMCs with a secondary antibody conjugated to a fluorescent dye; counting the PBMCs that express the antigen of interest; and calculating the percentage of PBMCs
- a determination of the proliferation frequency of antigen-expressing cells, including cells that express the CD4 antigen, in an animal having such cells is preferably accomplished by isolating periperhal blood mononuclear cells (PBMCs) from the animal; labeling the PBMCs with a suitable fluorescent dye; culturing the PBMCs with a suitable blastogenic medium; incubating the PBMCs with a mitogen; incubating the PBMCs with a monoclonal antibody specific for the antigen-expressing cell of interest; and determining the frequency with which the antigen-expressing cell of interest has proliferated.
- PBMCs periperhal blood mononuclear cells
- PBMCs are preferably isolated by gradient separation with a lymphocyte separation media.
- a suitable lymphocyte separation media is LSM® (ICN Biomedicals) .
- the counting of specific antigen- expressing cells, and the ultimate determination of the percentage of PBMCs that express that antigen is preferably accomplished by flow cytometry, more specifically fluorescence flow cytometry.
- flow cytometry consists of passing cells one at a time through a sensing zone of a flow cell. Since cells are passed through the flow cell one at a time, it is typically necessary to dilute the cell sample prior to analysis so that individual cells can be isolated for sensing.
- a fluorescence flow cytometer incorporates the principles of fluorescence cell analysis with light scatter. In general, this requires that the cells be stained with an appropriate color dye, or that a fluorochrome label be covalently attached to an antigen or antibody on the cells' surface thus indicating the occurrence of a specific antigen- antibody reaction.
- each particle that passes through the flow cell can be mapped into a feature space whose axes are the emission colors, light intensities, or other properties, i.e. scatter, measured by the detectors.
- the different particles in the sample can be mapped into distinct and non-overlapping regions of the feature space, allowing each particle to be analyzed based on its mapping in the feature space.
- the determination of the frequency with which an antigen-expressing cell has proliferated is preferably accomplished by flow cytometry, as described herein.
- Flow cytometric proliferation frequency data analysis is preferably accomplished with a proliferation module-containing software program such as ModFit LT (Verity Software House, Inc., Topsham, Maine).
- Proliferation frequency determination is based upon the principle that each generation of cells should have approximately half of the dye of the parental cells.
- a monoclonal antibody composition typically displays a single binding affinity for a particular protein with which it immunoreacts .
- a monoclonal antibody to an epitope of an antigen i.e., CD2
- CD2 an antigen
- a monoclonal antibody to an epitope of an antigen can be prepared by using a technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Kohler and Milstein, and the more recent human B cell hybridoma technique (Kozbor et al . , 1983), EBV-hybridoma technique (Cole et al . , 1985)), and trioma techniques. Other methods which can effectively yield monoclonal antibodies useful in the present invention include phage display techniques (Marks et al . , 1992)).
- Kohler and Milstein' s hybridoma technique begins with immunizing an animal with a protein or a fragment thereof.
- the immunization is typically accomplished by administering the immunogen to an immunologically competent mammal in an immunologically effective amount.
- the mammal is a rodent such as a rabbit, rat or mouse.
- the mammal is then maintained for a time period sufficient for the mammal to produce cells secreting antibody molecules that immunoreact with the immunogen.
- Such immunoreaction is detected by screening the antibody molecules so produced for immunoreactivity with a preparation of the immunogen protein.
- the antibody molecules may be desired to screen the antibody molecules with a preparation of the protein in the form in which it is to be detected by the antibody molecules in an assay, e.g., a membrane-associated form of the antigen (i.e., CD2 ) .
- an assay e.g., a membrane-associated form of the antigen (i.e., CD2 ) .
- CD2 a membrane-associated form of the antigen
- a suspension of antibody-producing cells removed from each immunized mammal secreting the desired antibody is then prepared. After a sufficient time, the mammal is sacrificed and somatic antibody-producing lymphocytes are obtained.
- Antibody-producing cells may be derived from the lymph nodes, spleens and peripheral blood of primed animals.
- Spleen cells are preferred, and can be mechanically separated into individual cells in a physiologically tolerable medium using methods well known in the art.
- Mouse lymphocytes give a higher percentage of stable fusions with the mouse myelomas described below.
- Rat, rabbit, and frog somatic cells can also be used.
- the spleen cell chromosomes encoding desired immunoglobulins are immortalized by fusing the spleen cells with myeloma cells, generally in the presence of a fusing agent such as polyethylene glycol (PEG) .
- PEG polyethylene glycol
- Any of a number of myeloma cell lines may be used as a fusion partner according to standard techniques .
- the resulting cells which include the desired hybridomas, are then grown in a selective medium, such as HAT medium, in which unfused parental myeloma or lymphocyte cells eventually die. Only the hybridoma cells survive and can be grown under limiting dilution conditions to obtain isolated clones.
- the supernatants of the hybridomas are screened for the presence of antibody of the desired specificity, such as by immunoassay techniques using the antigen that has been used for immunization. Positive clones can then be subcloned under limiting dilution conditions and the monoclonal antibody produced can be isolated.
- a selective medium such as HAT medium
- Hybridomas produced according to these methods can be propagated in vi tro or in vivo (in ascites fluid) using techniques known in the art.
- the individual cell line may be propagated in vitro, for example in laboratory culture vessels, and the culture medium containing high concentrations of a single specific monoclonal antibody can be harvested by decantation, filtration or centrifugation.
- the yield of monoclonal antibody can be enhanced by injecting a sample of the hybridoma into a histocompatible animal of the type used to provide the somatic and myeloma cells for the original fusion. Tumors secreting the specific monoclonal antibody produced by the fused cell hybrid develop in the injected animal.
- the body fluids of the animal such as ascites fluid or serum, provide monoclonal antibodies in high concentrations .
- DMEM Dulbecco's minimal essential medium
- Fluorescent labels which can be used in determining the percentage of an immune cell subtype present in a sample of PBMCs include, but are not limited to, phycoerythrin (PE) , fluorescein isothiocyanate (FITC) , allophycocyanin (APC) , Texas Red (TR, Molecular Probes, Inc.), peridinin chlorophyll complex (PerCp) , CY5 (Biological Detection System) and conjugates thereof coupled to PE (e.g., PE/CY5, PE/APC and PE/TR) .
- Fluorescent labels which can be used in determining the proliferation frequency of an immune cell subtype include, but are not limited to, the PKH dyes such as PKH2 , PKH26, and PKH67.
- the pigs were a product of three different internal genotypes: AxC, BXC and BXD genotypes. Eighteen boars in total were used in this trial; eight sires had more than ten offspring and the other ten sires had less than ten. The male to female ratio in the population was 1-1.3. Animal Flow Pigs were born at farm A, site I. Site I comprised the breeding, gestation, and farrowing units. The piglets were kept with the sow for a lactation period of approximately 19 days. Sows were fed to meet or exceed internal lactation curve guidelines.
- Pig flow took place in weekly batches through the farrowing, nursery, and grow-finishing rooms, and the pigs moved to the next stage when they met specific target weights.
- the target weight for nursery pigs was 4-6.5 kg, for the "on test” period was 31.7 kg, and to be "off test” was 122.31 kg.
- All pigs were processed 24 hours after birth. Each pig was weighed individually (Mosdal scale model IQ-plus 390-DC) and identified with button ear tags. Each pig was given a 1 cc mixture of iron dextran (Durvet, Inc) and penicillin (Pfizerpen® G, Pfizer) and 1 cc of gentamicin (Garacin®, Schering Plough) for scours prevention.
- each pig was individually weighed and color tagged. Pigs were transported to a nursery on site II where they were housed for at least seven weeks. Site II comprises the nurseries, and growing- finishing rooms. There were nine nurseries and pigs were penned by sex and weight for seven weeks and were housed equally distributed with other non-experimental pigs of the same age and product genotype. A total of 15 pigs/pen was targeted. A four-stage nursery program was implemented as well as a rigorous feed budget program. Pigs were vaccinated at 10 and 24 days of age with a Haemophilus parasuis bacterin (Suvaxyn® Respifend® Hps, Fort Dodge Laboratories).
- Blood was obtained from each pig at 6-7 weeks of age by puncturing the anterior vena cava, and was collected in two- 10 ml tubes containing anticoagulant (EDTA) . Blood samples were kept in coolers with ice packs at all times and sent by early overnight delivery for laboratory processing. The time between blood collection and laboratory processing was 20 hours or less. Blood was sampled in eleven batches to achieve manageable numbers for laboratory processing and a maximum of 25 blood samples were targeted per bleeding session.
- EDTA anticoagulant
- pigs were weighed and animals that reached the target weight of 31.7 kg were put "on test" by moving them out of the nurseries into the growing/finishing rooms. Two to four nursery rooms were used to fill one growing/ finishing room. Pigs were housed with other non- selected pigs of the same age and genotype. Selected pigs were equally represented in each pen. 60 barrows and 60 gilts were distributed over eight pens within a room in the finishing building. Six rooms of pens were available to house a total of 720 pigs. Pigs were housed with a minimum variation on temperature in all rooms (21.6°C high and 19.4°C low) and fed with a four-phase corn-soy based diet program.
- Each pig was individually weighed on test (True-Test model 700 scale) .
- live body measurements were taken, including back fat at the first rib, last rib (back fat) , last vertebrae, and loin depth with a real time ultrasound (Aloka model SSD-500 V) .
- Each pig was weighed every two weeks until the pigs reached the target off-test weight 122.3 kg.
- Farm A was considered to have a low to medium level of Salmonella exposure and to be Mycoplasma hyopneumoniae positive by historical serological studies.
- the farm was constantly monitored for detection of Salmonella antibodies using the Danish Mixed ELISA at Iowa State University.
- Results of Salmonella monitoring (ten finishing pigs/month) indicated that there was no active seroconversion during the present study, as seroconversion for Salmonella had occurred in previous years. No clinical signs of Salmonellosis were observed.
- Mycoplasma hyopneumoniae serology was evaluated yearly. During the last month of this study, 3/10 finishing pigs had antibodies against M. hyopneumoniae as detected by a Tween-ELISA test at the University of Minnesota Diagnostic Laboratory. Drug/Feed Additive Program
- peripheral blood mononuclear cells from all 199 pig blood samples were isolated by gradient separation using Lymphocyte separation media (LSM, Cappel, ICN Biomedicals, Ohio) as described elsewhere
- NK Natural killer cells
- NK cells are cells that possess the ability to kill certain tumor cells and a wide variety of virally infected cells. Such killing is part of natural rather than specific immunity.
- NK cells are identified as CD2+/CD16+ double positive cells using the CD2 and CD16 swine monoclonal antibodies (MAbs) MSA3 and G7 , respectively.
- the CD2 MAb detects T lymphocytes
- the CD16 MAb detects the Fc ⁇ receptor type III (Fc ⁇ RIII) .
- NK Killing of target cells by NK requires that the target cell be pre-coated with specific immunoglobulins (IgG) , and the lytic process is called antibody-dependent cell-mediated cytotoxicity .
- IgG immunoglobulins
- Recognition of bound antibody occurs through a low-affinity receptor for IgG Fc on the leukocyte, the Fc ⁇ RIII, which is detected in swine with the CD16 MAb.
- the SLA (swine Major Histocompatibility Complex) molecules play an important role in antigen recognition. They target specific antigens and therefore the SLA belongs to the specific immune system.
- MHC molecules There are two classes of MHC molecules, class I and class II.
- CD8+ cells are mostly cytotoxic T lymphocytes (CTL) and recognize peptide fragments bound to class I MHC molecules on cells that are targets of the lytic action of CTL. These peptides are generally derived from endogenously synthesized proteins such as viral antigens.
- CD4+ cells are mostly helper lymphocytes and recognize peptides bound to class II MHC molecules on the surface of other cells such as B cells, macrophages, and in pigs in some subsets of activated T cells.
- Class II associated peptides are usually derived from extracellular microbes and soluble protein antigens.
- CD4+ and CD8+ lymphocyte subsets can be detected using the 74-12-4 and 76- 2-11 MAbs, respectively.
- there are distinctive chromosomal regions such as DP, DQ, and DR.
- the SLA-DQ antibodies target the SLA-II antigen as SLA- DQ total (T) , bright or active (B) , and dull or less active (D) .
- the SLA-DQ MAb recognizes a monomorphic determinant on the SLA-DQ molecule which is thought to be a common component of the region and not a polymorphic determinant (the SLA-DQ gene expresses polymorphic products) .
- lymphoid cells were tested under two conditions. First, aliquots of PBMC were directly immunostained and the percentages of immune cell subsets determined by incubating the PBMC with primary swine MAb. Secondly, aliquots of PBMC were cultured with the mitogen Concanavalin A (ConA, Sigma, St. Louis, MO) and proliferative response of cell subsets determined using flow cytometry and combined MAb and PKH67 staining (Sigma, St.
- the monoclonal antibodies and their target cells in the PBMC population are listed in Table 1. All monoclonal antibodies used in this study were specific for swine and the specificity to the target cell has been described elsewhere (Saalmueller et al . , 1998 and Haverson et al . , 2000). These MAbs were chosen because they target surface markers that are expressed on monocytes and lymphocytes. An anti-swine pan leukocyte marker (CD45) and multiple IgG isotype control MAbs were used as positive and negative controls respectively.
- CD45 anti-swine pan leukocyte marker
- IgG isotype control MAbs were used as positive and negative controls respectively.
- the percentage of cells immunostained with the specific MAbs was determined after labeling cells with secondary monoclonal antibodies coupled with FITC or PE (Southern Biotechnology Associates, Birmingham, AL) .
- PBMC Flow Cytometric Analyses Immunostained PBMC were analyzed using flow cytometry as described elsewhere (Solano-Aguilar et al . 2001). The percentage of stained cells was calculated based on the fluorescence intensity using the IgG isotype background as a control. For certain markers it is important to distinguish between dull (D) and bright (B) immunofluorescence thus, for SLA-DQ, the total (T) , D and B populations are reported. The flow cytometric analysis for each sample included 16,000 to 20,000 events. PKH67 Staining For proliferation testing, PBMC were washed once in RPMI 1640 medium, followed by filtering through a nylon mesh in a 17 x 100 ml polypropylene conical tube.
- the cell pellet was taken up in Diluent C (Sigma, St. Louis, MO) to achieve a final suspension of 5 x 10 6 cells/ml. This cell suspension was then added to an equal volume of PKH67 dye stock (1.5 L dye/ 1 x 10 cells) and incubated for three minutes at room temperature. Cell concentrations were previously established to stain cells homogenously and bright. A volume of heat inactivated, fetal bovine serum equal to the total volume of cells + dye was added to the suspension.
- Diluent C Sigma, St. Louis, MO
- the cells were then centrifuged to a pellet three times, washed the first time with RPMI medium with serum and the final time in blastogenic media (RPMI 1640 supplemented with 5% FBS, 1 mM sodium pyruvate, 2mM L-glutamine, non-essential amino acids, 5.5 x 10 "5 M 2-Mercaptoethanol, 25mM Hepes buffer) , and counted with a hemacytometer . Homogeneity of the staining procedure was checked by flow cytometry on day 0 for an aliquot of these labeled cells.
- Flow cytometry data was analyzed with the Proliferation Wizard module in ModFit LT software (Verity Software House, Inc., Topsham, Maine) . Cells were gated according to the forward and side scattered signals of the lymphocyte population to exclude debris. The intensity of the non- proliferating (parental) cells was determined by analysis of the sample that had been cultured without mitogen. Each generation of cells should have approximately half the PKH67 dye of the parental cells. Working down from the intensity of the parental generation, the ModFit software deconvolutes the fluorescence intensity histogram with Gaussian distributions centered on the peak at different channel intervals (Givan et al . , 1999).
- the individual frequency of each cell subset (CD4+, CD8+, PKH67+) in the original population that had proliferated was calculated.
- the proliferation index (PI) was calculated as the sum of the cells in all generations divided by the number of original parent cells theoretically present in the non-stimulated population. The PI is a measure of the increase in cell number in the culture over the course of the experiment (three days) . Precursor frequencies and proliferation indexes were used are measurements of lymphocyte proliferation and are considered the functional assays in this study.
- the productive parameters evaluated included average daily gain (ADG) at the following production stages: a) on test, b) from birth to weaning, c) birth to off test or lifetime daily gain, d) weaning to off test, and e) weaning to on test. Additional productive parameters such as live body and carcass measurements, feed intake, and feed conversion were also analyzed.
- ADG average daily gain
- the data analyzed by flow cytometry with the ModFit program indicated that 99.37 % of cells were stained with PKH67 demonstrating the high efficiency of the procedure.
- the results obtained with the CD45 panleukocyte MAb indicated that an average of 92.04 % of the cells isolated were recognized by the CD45 monoclonal antibody as leukocytes, which indicated an appropriate lymphoid gate. Background staining was controlled by the use of IgG isotype controls. All MAb used showed higher values than the background controls indicating that the detection system was effective.
- the proportion of the immune marker detected in the blood is given for a typical pig (pig 1867): CD4 (14.92%), CD8 (48.24%), CD4/CD8 (8.32%) SWC3 (4.12%), SLADQ T (46.4%) SLADQB (16.34%), SLADQ D (30.06%), CD16 (20.16%) CD2 (63.32%), CD2/CD16 (18.98%), CD21 (7.26%).
- the percentages for the controls were: IgGa/Ig2b (0.4/0%), Ig2a/IgGl (0.22/.06, CD45 (98.38).
- some immune cell subsets like CD8 , CD16, CD2/CD16 were relatively abundant.
- the relative percentages of other markers such as SWC3 and CD21 were less common in the circulating blood but yet several times above the background level .
- the average weaning weight was 6.4 kg ⁇ 0.16, and the average weaning age was 19.4 days ⁇ 0.2. At weaning, 76% of the piglets fell within the 9.0-14.5 pounds weight range; from the rest, 1% of the pigs fell below a weight of ⁇ 8.9 pounds and 23% were >14.6 pounds.
- the average initial on test weight was 33.3 kg ⁇ 0.5 and the average on test age was 70.8 days ⁇ 0.6.
- Average off test weight was 123.1 kg ⁇ 0.7 and average off test age was 166.8 days ⁇ 0.9.
- the average number of days to market was calculated by dividing the target off test weight of 116 kg by the ADG of the top versus the bottom 30 pigs.
- This means the predicted difference in lifetime gain is (33.1-5.4) x .0018 .0498 kg/day.
- the difference between high and low % of CD2+/CD16+ cells was about 8.32 kg.
- Pigs that have a higher proportion of double positive cells had an ADG of 0.7556 kg, so to reach the target off test weight of 116 kg they required in average 156 days. Pigs expressing a high proportion of CD2+/CD16+ cells required 166 days to reach the same target weight making a difference of ten days between groups. Some phenotypic markers and proliferative responses were significantly associated with ADG at specific production stages but not to the entire productive life of the pig.
- the correlation was positive, higher proportion of SLA-DQB and T positive cells was associated with greater hot carcass weight (Table 4) .
- SLA-DQ markers were also associated with feed conversion.
- NK cells possess the ability to kill certain tumor cells and a wide variety of virally infected cells. Such killing is not induced by specific antigen and is thus part of natural rather than specific immunity. NK cells are capable of lysing various target cells.
- the level of NK- mediated cytotoxicity is typically not regulated by the antigen but by cytokines and hormones like interleukin-2 , interferons (IFN), prolactin, and growth hormone. NK cells also secrete IFN-gamma which activates monocytes to develop into macrophages .
- CD2 expression in human occurs on thymic cells, peripheral T cells, and natural killer cells. It is also expressed on 50% of thymic B cells and expression on mature B cells is controversial.
- the CD16 detects the Fc ⁇ RIII.
- a subset of NK cells are considered to be CD2+/CD16+.
- the CD16 cell subset is mainly expressed by T and NK cells but B cells may also express it.
- B and NK cells are CD3 negative.
- NK cells in pig are divided between CD8- and CD8 dull cells. The role of the B cells as a source of CD16+ cell subsets in this study may not be significant since there were no associations between the B cell antigen (CD21) and ADG.
- CD8+ cells are mostly cytotoxic T lymphocytes (CTL) and recognize peptide fragments bound to class I MHC molecules on cells that are targets of the lytic action of CTL. These peptides are generally derived from endogenously synthesized proteins such as viral antigens. MHC class I antigens were not targeted in this study.
- CTL cytotoxic T lymphocytes
- MHC class I antigens were not targeted in this study.
- CD4+ lymphocytes are mostly helper cells and recognize peptides bound to class II MHC molecules on the surface of other cells such as B cells, macrophages, and in pigs in some subsets of activated T cells.
- Class II associated peptides are usually derived from extracellular microbes and soluble protein antigens .
- the proportion of SLA-DQ+ cells showed significant associations with carcass traits and feed conversion.
- the SLA or swine MHC molecules play an important role in antigen recognition.
- the SLA-DQ swine MAb targets the SLA class II antigen, which is thought to be equivalent to the murine MHC class II locus, I-E, and human HLA-DQ.
- the DQ region comprises loci for alpha and beta chains; SLADQ is usually a heterodimer of one alpha and one beta chain which is the surface expressed product detected by the antibody.
- the SLA-DQ monoclonal antibody recognizes a monomorphic determinant on the SLA-DQ molecule which is thought to be a conserved sequence of one of the genes in the SLA-DQ genes .
- the SWC3 MAb was associated to ADG in limited production stages.
- SWC3 targets mononuclear cells.
- Mononuclear cells represent a cell population that is critical in natural immunity, and also plays a central role in specific acquired immunity. Some functions of the monocyte are phagocytosis of foreign particles, production of mediators to kill microbes and control the spread of infections, production of cytokines and growth factors, antigen-presenting cell function, and promotion of T cell activation.
- lymphocyte proliferation had a detrimental effect on production parameters such ADG and feed conversion. It has been reported that under acute Salmonella challenge, lymphocyte proliferation is a good indicator of Salmonella resistance and growth. In that study higher proliferative responses of blood lymphocytes prior to challenge were associated with decreased disease resistance and growth under experimental conditions (Van Diemen et al . , submitted) . In the present study, high proliferative responses were associated with detrimental effects on production parameters including growth which could possibly be associated with resistance to subclinical diseases. Most importantly, this detrimental effect was observed in a commercial setting in a herd with no particular acute disease and it could be an indicator of robustness .
- Microbial exposure occurs in any environment that is not completely sterile. Microbial exposure certainly occurs in the cleanest commercial operations. Pig exposure to specific pathogenic agents was not assessed in this study but the association results (ADG) point to the involvement of key immune cells that act in response to viral (NK cells, CD8+ cells) and bacterial infections (CD4+, SLA-DQ+, monocytes) . This seems to be relevant even in an environment where there are not evident clinical signs of viral infectious such in the case of farm A.
- Vaccination with a Haemophilus parasuis bacterin was administered at days 10 and 24 days of age at the pre-nursery and nursery stages .
- the second vaccination was given at least three weeks before blood was collected for cell characterization. Because the time lapse after the second vaccination was at least three weeks before blood samples were collected for immunostaining, it is speculated that vaccination did not have a significant impact on the immune cell populations.
- the size of the pig population studied was increased to an additional 286 pigs.
- the goal was to collect more data to confirm the associations between the immune phenotypes (CD16, CD2/CD16, CD8) and productive performance (growth) .
- the pigs included in this study originated from 2 different farms, one of the farms was the same from Example 1.
- the management of the animals, the productive performance recording, and the measurement of immunological traits was similar to the one described in Example 1.
- the statistical analysis was performed in an identical fashion to the one described in Example 1.
- the association analysis reported for the 1 st year included 139 animals.
- the 1 st and 2 nd year results are presented together for total of 425 animals. See Table 5 below.
- CD2/CD16 CD2/CD16
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39072502P | 2002-06-21 | 2002-06-21 | |
US390725P | 2002-06-21 | ||
PCT/US2003/019581 WO2004000009A2 (en) | 2002-06-21 | 2003-06-20 | Methods for selection for efficient animal growth |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1581043A2 true EP1581043A2 (en) | 2005-10-05 |
EP1581043A4 EP1581043A4 (en) | 2006-08-09 |
Family
ID=30000606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03737208A Withdrawn EP1581043A4 (en) | 2002-06-21 | 2003-06-20 | Methods for selection for efficient animal growth |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1581043A4 (en) |
CN (1) | CN1717586A (en) |
AU (1) | AU2003238311A1 (en) |
BR (1) | BR0311977A (en) |
CA (1) | CA2489990A1 (en) |
MX (1) | MXPA04012934A (en) |
WO (1) | WO2004000009A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102017918B (en) * | 2010-09-27 | 2012-07-04 | 大连海洋大学 | Method for feeding broad-spectrum disease-resistant sea farming through immunopolysaccharide means |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014064A1 (en) * | 1992-12-09 | 1994-06-23 | University Of Guelph | Methodology for developing a superior line of domesticated animals |
US6287564B1 (en) * | 1997-12-24 | 2001-09-11 | Lauraine Wagter-Lesperance | Method of identifying high immune response animals |
-
2003
- 2003-06-20 MX MXPA04012934A patent/MXPA04012934A/en not_active Application Discontinuation
- 2003-06-20 AU AU2003238311A patent/AU2003238311A1/en not_active Abandoned
- 2003-06-20 BR BRPI0311977-7A patent/BR0311977A/en not_active IP Right Cessation
- 2003-06-20 CA CA002489990A patent/CA2489990A1/en not_active Abandoned
- 2003-06-20 CN CN 03819134 patent/CN1717586A/en active Pending
- 2003-06-20 WO PCT/US2003/019581 patent/WO2004000009A2/en not_active Application Discontinuation
- 2003-06-20 EP EP03737208A patent/EP1581043A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014064A1 (en) * | 1992-12-09 | 1994-06-23 | University Of Guelph | Methodology for developing a superior line of domesticated animals |
US6287564B1 (en) * | 1997-12-24 | 2001-09-11 | Lauraine Wagter-Lesperance | Method of identifying high immune response animals |
Non-Patent Citations (11)
Title |
---|
GLEW E J ET AL: "Antigen-presenting cells from calves persistently infected with bovine viral diarrhoea virus, a member of the Flaviviridae, are not compromised in their ability to present viral antigen" JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 82, no. 7, July 2001 (2001-07), pages 1677-1685, XP002314006 ISSN: 0022-1317 * |
MALLARD B A ET AL: "IMMUNE RESPONSIVENESS IN SWINE: EIGHT GENERATIONS OF SELECTION FOR HIGH AND LOW IMMUNE RESPONSE IN YORKSHIRE PIGS" PROCEEDINGS OF THE WORLD CONGRESS OF GENETICS APPLIED TO LIVESTOCK PRODUCTION, 1998, pages 1-8, XP001155297 * |
MALLARD B A ET AL: "THE EFFECT OF SWINE LEUKOCYTE ANTIGEN HAPLOTYPE ON BIRTH AND WEANING WEIGHTS IN MINIATURE PIGS AND THE ROLE OF STATISTICAL ANALYSIS IN THIS ESTIMATION" JOURNAL OF ANIMAL SCIENCE, vol. 69, no. 2, 1991, pages 559-564, XP002386966 ISSN: 0021-8812 * |
MALLARD B A ET AL: "Use of estimated breeding values in a selection index to breed Yorkshire pigs for high and low immune and innate resistance factors" ANIMAL BIOTECHNOLOGY, NEW YORK, NY, US, vol. 3, no. 2, 1992, pages 257-280, XP009018764 ISSN: 1049-5398 * |
MASHALY M M ET AL: "Influence of genetic selection for antibody production against sheep blood cells on energy metabolism in laying hens" POULTRY SCIENCE, vol. 79, no. 4, April 2000 (2000-04), pages 519-524, XP008065736 ISSN: 0032-5791 * |
See also references of WO2004000009A2 * |
SEGALES J ET AL: "Changes in peripheral blood leukocyte populations in pigs with natural postweaning miltisystemic wasting syndrome (PMWS)" VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, AMSTERDAM, NL, vol. 81, no. 1-2, 30 August 2001 (2001-08-30), pages 37-44, XP002988813 ISSN: 0165-2427 * |
SONGSERM T ET AL: "Cellular immune response in the small intestine in two broiler chicken lines orally inoculated with malabsorption syndrome homogenates" VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, AMSTERDAM, NL, vol. 85, no. 1-2, February 2002 (2002-02), pages 51-62, XP002988812 ISSN: 0165-2427 * |
THOLEN E ET AL: "The genetic foundation of fitness and reproduction traits in Australian pig populations: 2. Relationships between weaning to conception interval farrowing interval, stayability, and other common reproduction and production traits" AUSTRALIAN JOURNAL OF AGRICULTURAL RESEARCH, vol. 47, no. 8, 1996, pages 1275-1290, XP008065727 ISSN: 0004-9409 * |
WILKIE B ET AL: "SELECTION FOR HIGH IMMUNE RESPONSE: AN ALTERNATIVE APPROACH TO ANIMAL HEALTH MAINTENANCE?" VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, AMSTERDAM, NL, vol. 72, no. 1/2, 15 December 1999 (1999-12-15), pages 231-235, XP001155531 ISSN: 0165-2427 * |
WILKIE B N ET AL: "MULTI-TRAIT SELECTION FOR IMMUNE RESPONSE: A POSSIBLE ALTERNATIVE STRATEGY FOR ENHANCED LIVESTOCK HEALTH AND PRODUCTIVITY" PROGRESS IN PIG SCIENCE, 1998, pages 29-38, XP001155604 * |
Also Published As
Publication number | Publication date |
---|---|
EP1581043A4 (en) | 2006-08-09 |
BR0311977A (en) | 2007-05-22 |
WO2004000009A3 (en) | 2005-08-11 |
CA2489990A1 (en) | 2003-12-31 |
CN1717586A (en) | 2006-01-04 |
MXPA04012934A (en) | 2005-10-18 |
WO2004000009A2 (en) | 2003-12-31 |
AU2003238311A1 (en) | 2004-01-06 |
AU2003238311A8 (en) | 2004-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Greenlee et al. | Lymphomas in dogs a morphologic, immunologic, and clinical study | |
Solano-Aguilar et al. | Isolation and purification of lymphocyte subsets from gut-associated lymphoid tissue in neonatal swine | |
Degefu et al. | Seroprevalence of bovine brucellosis in agro pastoral areas of Jijjiga zone of Somali National Regional State, Eastern Ethiopia | |
Gratama et al. | Analysis of variation in results of CD34+ hematopoietic progenitor cell enumeration in a multicenter study | |
Hlavova et al. | The phenotype and activation status of T and NK cells in porcine colostrum suggest these are central/effector memory cells | |
Jacobs et al. | Production and related variables in bovine leukaemia virus-infected cows | |
Mitra et al. | Vaccination against histomonosis limits pronounced changes of B cells and T-cell subsets in turkeys and chickens | |
Grøndahl-Rosado et al. | NCR1 is an activating receptor expressed on a subset of canine NK cells | |
Galina-Pantoja et al. | Relationship between immune cell phenotypes and pig growth in a commercial farm | |
US20040259169A1 (en) | Methods for selection for efficient animal growth | |
Li et al. | Flow cytometric analysis of T lymphocyte subpopulations in large-bodied turkey lines and a randombred control population | |
Platt et al. | Canine peripheral blood lymphocyte phenotyping by 7-color multiparameter flow cytometry | |
Cook et al. | A screen of mammalian antibodies on snapper (Pagrus auratus, Sparidae) peripheral blood leukocytes reveals cross reactivity of an anti-human CD3 antibody with a population of mIg− cells | |
Zelnickova et al. | Age-dependent changes of proinflammatory cytokine production by porcine peripheral blood phagocytes | |
Andrišić et al. | Phenotype analysis of CD3+ CD16+ lymphocytes in the peripheral blood of pigs | |
EP1581043A2 (en) | Methods for selection for efficient animal growth | |
Cheeseman et al. | Genetic line effect on peripheral blood leukocyte cell surface marker expression in chickens | |
Kurokawa et al. | Immunohistochemical identification of T and B lymphocytes in formalin-fixed paraffin-embedded chicken tissues using commercial antibodies | |
Wilson et al. | An examination of some physiological variables for assessing the welfare of beef cattle in feedlots | |
Faldyna et al. | Flow cytometric analysis of bone marrow leukocytes in neonatal dogs | |
Namavari | Neosporosis in Iran; recent evidences and perspectives | |
Deravi et al. | T‐Cell Tumors | |
Morris, SD*, Myburgh, JG**, Van Vuuren, M.*** & Van der Vyver | Serological survey to determine the prevalence of bovine leukaemia virus antibodies in dairy cattle on selected farms in the Gauteng and Mpumalanga Provinces | |
Olobo et al. | In vitro secretion of bovine immunoglobulins during pokeweed mitogen or pokeweed mitogen and antigen activation of lymphocytes | |
Sinkora et al. | Monoclonal antibodies putatively recognising activation and differentiation antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20041228 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/50 20060101ALI20060629BHEP Ipc: A01K 1/00 20060101AFI20040113BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060712 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/53 20060101AFI20061127BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20061012 |